DocWire News Editors

DocwireNews

Survivors of childhood cancer who were treated with chest radiation may be at an increased risk for breast cancer. Children’s Oncology Group (COG) guidelines recommend annual mammography with breast magnetic resonance imaging (MRI), but the benefits and costs of these screenings are uncertain. A modeling study presented at the 2019 ASCO Annual Meeting found that screening at-risk survivors reduces mortality and is cost-effective.
 Researchers used two breast cancer simulation models from the Cancer Intervention and Surveillance Modeling Network and data from the Childhood Cancer Survivor Study to reflect high breast cancer and competing mortality risks among survivors. They simulated three screening strategies: annual mammography with MRI starting at 25 years of age (COG25), annual MRI starting at 25 years of age (MRI25), and biennial mammography starting at 50 years of age (Mammo50). Costs and quality of life weights were based on U.S. averages and published studies.
 Among a simulated cohort of 25-year-old survivors treated with chest radiation, the lifetime breast cancer mortality risk in the absence of screening was 10% to 11% across the models. Compared with no screening, Mammo50, MRI25, and COG25 screening strategies averted approximately 23% to 25%, 56% to 62%, and 56% to 71% of deaths, respectively. See TABLE for all outcomes for each of the two models.
The authors concluded that initiating annual screening at a younger age among at-risk survivors could prevent more than 50% of breast cancer-related deaths. “Additional data on test performance are needed to inform recommendations on screening modality,” they concluded.
<table width="696">
<tbody>
<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86"> </td>
<td colspan="4" width="304">Model 1</td>
</tr>
<tr style="mso-yfti-irow: 1; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">Strategy</td>
<td width="67">False-positive tests*</td>
<td width="95">Incremental costs*†</td>
<td width="75">QALYs gained*†</td>
<td width="67">ICER</td>
</tr>
<tr style="mso-yfti-irow: 2; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">Mammo50</td>
<td width="67">259</td>
<td width="95">–</td>
<td width="75">–</td>
<td width="67">–</td>
</tr>
<tr style="mso-yfti-irow: 3; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">No screening</td>
<td width="67">0</td>
<td width="95">1,033,840</td>
<td width="75">-74.4</td>
<td width="67">‡</td>
</tr>
<tr style="mso-yfti-irow: 4; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">MRI25</td>
<td width="67">3,283</td>
<td width="95">5,629,340</td>
<td width="75">285.3</td>
<td width="67">$19,730</td>
</tr>
<tr style="mso-yfti-irow: 5; mso-yfti-lastrow: yes; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">COG25</td>
<td width="67">4,188</td>
<td width="95">8,439,630</td>
<td width="75">350.5</td>
<td width="67">$43,100</td>
</tr>
</tbody>
</table>
&nbsp;
<table width="696">
<tbody>
<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86"> </td>
<td colspan="4" width="304">Model 2</td>
</tr>
<tr style="mso-yfti-irow: 1; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">Strategy</td>
<td width="67">False-positive tests*</td>
<td width="95">Incremental costs*†</td>
<td width="75">QALYs gained*†</td>
<td width="67">ICER</td>
</tr>
<tr style="mso-yfti-irow: 2; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">Mammo50</td>
<td width="67">257</td>
<td width="95">–</td>
<td width="75">–</td>
<td width="67">–</td>
</tr>
<tr style="mso-yfti-irow: 3; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">No screening</td>
<td width="67">0</td>
<td width="95">$839,750</td>
<td width="75">-65.4</td>
<td width="67">‡</td>
</tr>
<tr style="mso-yfti-irow: 4; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">MRI25</td>
<td width="67">3,764</td>
<td width="95">6,651,870</td>
<td width="75">175.4</td>
<td width="67">$37,920</td>
</tr>
<tr style="mso-yfti-irow: 5; mso-yfti-lastrow: yes; mso-prop-change: 'Tsagan Garyaeva' 20190604T1033;">
<td width="86">COG25</td>
<td width="67">4,879</td>
<td width="95">9,463,560</td>
<td width="75">171.6</td>
<td width="67">‡</td>
</tr>
</tbody>
</table>
<table width="696">
<tbody>
<tr>
<td width="696">&nbsp;
*Per 1,000
†Discounted
‡Dominated
QALYs = quality-adjusted life-years; ICER = incremental cost-effectiveness ratio</td>
</tr>
</tbody>
</table>
 
Reference 
Yeh J, Lowry KP, Schechter CB, et al. Clinical outcomes and cost-effectiveness of breast cancer screening for childhood cancer survivors treated with chest radiation: A comparative modeling study. Abstract #6525. Presented at the 2019 ASCO Annual Meeting, Chicago, IL, June 1, 2019.
&nbsp;

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Survivors of childhood cancer treated with chest radiation at an increased risk for breast cancer

ASCO 2019

Survivors of childhood cancer who were treated with chest radiation may be at an increased risk for breast cancer. Children’s Oncology Group (COG) guidelines recommend ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe